Angiotensin Converting Enzyme Inhibitors and Periprocedural Myocardial Infarction
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02054390 |
Recruitment Status
:
Completed
First Posted
: February 4, 2014
Last Update Posted
: June 20, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Metabolic Syndrome Coronary Artery Disease |
Study Type : | Observational |
Actual Enrollment : | 459 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Angiotensin Converting Enzyme Inhibitor Therapy and Periprocedural Myocardial Infarction in Patients With Metabolic Syndrome |
Study Start Date : | February 2014 |
Actual Primary Completion Date : | June 2014 |
Actual Study Completion Date : | June 2014 |
- Periprocedural myocardial injury (MI) [ Time Frame: 24 hours after (percutaneous coroary intervention) PCI ]Periprocedural MI was defined as cardiac Troponin I release [5 times ULN] 24 hours after percutaneous coronary intervention
- Periprocedural myonecrosis [ Time Frame: 24 hours after PCI ]Peri-procedural myonecrosis was defined as troponin I release of >1×ULN 24 hours after the intervention.
- inflammatory marker [ Time Frame: 24 hours after PCI ]high sensitive C-reactive protein measurement 24 hours after PCI

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Metabolic syndorme (MS) was defined as the presence of 3 or more of these components:
- high fasting glucose (fasting serum glucose ≥100 mg/dl or drug treatment for elevated blood glucose)
- abdominal obesity (given as waist circumference >102 cm in men and >88 cm in women)
- high blood pressure (>130/>85 mmHg or drug treatment for hypertension)
- hypertriglyceridemia (serum triglycerides ≥150 mg/dl)
- low high-density lipoprotein (HDL) cholesterol (<40 mg/dl in men and <50 mg/dl in women).
Inclusion Criteria:
- metabolic syndrome
- elective percutaneous coronary intervention with angiographically successful stent implantation
Exclusion Criteria:
- acute coronary events
- renal failure
- needed the use of IV glycoprotein IIb/IIIa receptor inhibitors were excluded
- left main coronary artery disease
- chronic total occlusion
- high levels of baseline CKMB or troponin
- any contraindication of aspirin, clopidogrel or ACEi treatment

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02054390
Turkey | |
Ankara University School Of Medicine, Department of Cardiology | |
Ankara, Turkey, 06230 |
Responsible Party: | Özgür Ulaş Özcan, MD, Ankara University |
ClinicalTrials.gov Identifier: | NCT02054390 History of Changes |
Other Study ID Numbers: |
ACEmetsend |
First Posted: | February 4, 2014 Key Record Dates |
Last Update Posted: | June 20, 2014 |
Last Verified: | June 2014 |
Keywords provided by Özgür Ulaş Özcan, Ankara University:
Angiotensin converting enzyme inhibitor inflammation metabolic syndrome |
myonecrosis percutaneous coronary intervention periprocedural myocardial injury |
Additional relevant MeSH terms:
Syndrome Infarction Coronary Artery Disease Myocardial Ischemia Coronary Disease Myocardial Infarction Metabolic Syndrome X Disease Pathologic Processes Ischemia Necrosis Heart Diseases |
Cardiovascular Diseases Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases Insulin Resistance Hyperinsulinism Glucose Metabolism Disorders Metabolic Diseases Enzyme Inhibitors Angiotensin-Converting Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Protease Inhibitors |